The phosphoinositide 3-Kinase pathway is crucial for the growth of canine mast cell tumors

Journal of Veterinary Medical Science

Volumn 75, Issue 6, 2013, Pages 791-794

  Amagai, Yosuke ^a   Tanaka, Akane ^a   Matsuda, Akira ^a   Oida, Kumiko ^a   Jung, Kyungsook ^a   Matsuda, Hiroshi ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Mast cell tumor; Pi3K signaling

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; STEM CELL FACTOR RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL PROLIFERATION; DOG; DOG DISEASE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MASTOCYTOMA; METABOLISM; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MASTOCYTOMA; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION;

CANIS FAMILIARIS;

EID: 84879585314     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.12-0540     Document Type: Article

References (32)

1. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. and Saltiel, A. R. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270: 27489-27494. [Medline]
2. Amagai, Y., Tanaka, A., Ohmori, K. and Matsuda, H. 2008. Establishment of a novel high-affinity IgE receptor-positive canine mast cell line with wild-type c-kit receptors. Biochem. Biophys. Res. Commun. 366: 857-861. [Medline] [CrossRef]
3. Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J. M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J. C., Debled, M., Spaëth, D., Legouffe, E., Allouache, D., El Kouri, C. and Pujade-Lauraine, E. 2012. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30: 2718-2724. [Medline] [CrossRef]
4. Brown, E. J., Albers, M. W., Shin, T. B., Ichikawa, K., Keith, C. T., Lane, W. S. and Schreiber, S. L. 1994. A mammalian protein target by G1-arresting rapamycin-receptor complex. Nature 369: 756-758. [Medline] [CrossRef]
5. Buitenhuis, M. and Coffer, P. J. 2009. The role of the PI3K-PKB signaling module in regulation of hematopoiesis. Cell Cycle 8: 560-566. [Medline] [CrossRef]
6. Camps-Palau, M. A., Leibmann, N. F., Elmslie, R., Lana, S. E., Plaza, S., McKnight, J. A., Risbon, R. and Bergman, P. J. 2007. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet. Comp. Oncol. 5: 156-167. [Medline] [CrossRef]
7. Caughey, G. H., Lazarus, S. C., Viro, N. F., Gold, W. M. and Nadel, J. A. 1988. Tryptase and chymase: comparison of extraction and release in two dog mastocytoma lines. Immunology 63: 339-344. [Medline]
8. Gilfillan, A. M. and Tkaczyk, C. 2006. Integrated signaling pathways for mast-cell activation. Nat. Rev. Immunol. 6: 218-230. [Medline] [CrossRef]
9. Hahn, K. A., Legendre, A. M., Shaw, N. G., Phillips, B., Ogilvie, G. K., Prescott, D. M., Atwater, S. W., Carreras, J. K., Lana, S. E., Ladue, T., Rusk, A., Kinet, J. P., Dubreuil, P., Moussy, A. and Hermine, O. 2010. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am. J. Vet. Res. 71: 1354-1361. [Medline] [CrossRef]
10. Hayes, A., Adams, V., Smith, K., Maglennon, G. and Murphy, S. 2007. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet. Comp. Oncol. 5: 168-176. [Medline] [CrossRef]
11. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A. and Zigler, A. J. 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932. [Medline]
12. Jusko, W. J. and Rose, J. Q. 1980. Monitoring prednisone and prednisolone. Ther. Drug Monit. 2: 169-176. [Medline] [Cross-Ref]
13. Kim, M. S., Radinger, M. and Gilfillan, M. 2008. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol. 29: 493-501. [Medline] [CrossRef]
14. London, C. A., Galli, S. J., Yuuki, T., Hub, Z. Q., Helfand, S. C. and Geisslerb, E. N. 1999. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27: 689-697. [Medline] [CrossRef]
15. London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., Bergman, P. J., Couto, G. C., Mauldin, G. N. and Michels, G. M. 2009. Multi-center, placebocontrolled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 15: 3856-3865. [Medline] [CrossRef]
16. Ma, P., Mali, R. S., Munugalavadla, V., Krishnan, S., Ramdas, B., Sims, E., Martin, H., Ghosh, J., Li, S., Chan, R. J., Krystal, G., Craig, A. W., Takemoto, C. and Kapur, R. 2011. The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor. Blood 118: 3459-3469. [Medline] [Cross-Ref]
17. Matsuda, A., Tanaka, A., Amagai, Y., Ohmori, K., Nishikawa, S., Xia, Y., Karasawa, K., Okamoto, N., Oida, K., Jang, H. and Matsuda, H. 2011. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells. Vet. Immunol. Immunopathol. 144: 321-328. [Medline] [CrossRef]
18. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A. and Roifman, C. M. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648. [Medline] [CrossRef]
19. Morales, J. K., Falanga, Y. T., Depcrynski, A., Fernando, J. and Ryan, J. J. 2010. Mast cell homeostasis and the JAK-STAT pathway. Genes Immun. 11: 599-608. [Medline] [CrossRef]
20. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., Urbanowitz, G., Berg, W. J., Kay, A., Lebwohl, D. and Ravaud, A. 2008. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456. [Medline] [CrossRef]
21. Ohmori, K., Kawarai, S., Yasuda, N., Tanaka, A., Matsuda, H., Nishimura, R., Sasaki, N., Tsujimoto, H. and Masuda, K. 2008. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. Vet. Immunol. Immunopathol. 126: 43-53. [Medline] [CrossRef]
22. Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., Green, A., Mayeux, P., Lacombe, C. and Bouscary, D. 2010. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95: 819-828. [Medline] [CrossRef]
23. Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., Oberg, K., Van Cutsem, E. and Yao, J. C. 2011. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Lancet 378: 2005-2012. [Medline] [CrossRef]
24. Sellge, G., Lorentz, A., Gebhardt, T., Levi-Schaffer, F., Bektas, H., Manns, M. P., Schuppan, D. and Bischoff, S. C. 2004. Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J. Immunol. 172: 260-267. [Medline]
25. Shin, J., Pan, H. and Zhong, X. P. 2012. Regulation of mast cell survival and function by tuberous sclerosis complex 1. Blood 119: 3306-3314. [Medline] [CrossRef]
26. Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E. and McCubrey, J. A. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218. [Medline] [Cross-Ref]
27. Tanaka, A., Konno, M., Muto, S., Kambe, N., Morii, E., Nakahata, T., Itai, A. and Matsuda, H. 2005. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324-2331. [Medline] [CrossRef]
28. Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269: 5241-5248. [Medline]
29. Ward, A. C., Touw, I. and Yoshimura, A. 2000. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95: 19-29. [Medline]
30. Withrow, S. J. and Vail, D. M. 2008. Small Animal Clinical Oncology, 4th ed., B.W. Saunders, Philadelphia.
31. Zemke, D., Yamini, B. and Yuzbasiyan, V. 2002. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet. Pathol. 39: 529-535. [Medline] [CrossRef]
32. Zhang, W. and Liu, H. T. 2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12: 9-18. [Medline] [CrossRef]